Health Canada approves 1st RSV vaccine for older adults

Click to play video: 'RSV wave—are our seniors at risk?'
RSV wave—are our seniors at risk?
With pediatric emergencies overwhelmed with a recent wave of RSV, health experts warn seniors could be the next victims. Dr. Mitch Schulman joins Global’s Laura Casella to talk about a potential vaccine and how to protect them this Holiday season – Nov 30, 2022

Health Canada has approved the first vaccine for respiratory syncytial virus (RSV) for adults aged 60 and over.

Doctors have been calling for an RSV vaccine for seniors because although the virus is common, older people are much more likely to become severely ill and require hospitalization.

RSV season in Canada usually starts in the late fall and lasts until spring.

In a news release issued on Friday, manufacturer GSK said a randomized clinical trial showed the vaccine, called Arexvy, was 82 per cent effective at preventing lower respiratory tract disease caused by RSV compared to seniors who got a placebo.

The company said it was 94 per cent effective at preventing the illness in seniors with underlying medical conditions.

Health Canada confirmed the vaccine’s approval in an email to Global News Friday.

Story continues below advertisement

For most people, including children, RSV usually causes a mild infection that goes away within a couple of weeks, according to the Public Health Agency of Canada’s website.

Click to play video: 'Researchers close to RSV vaccine'
Researchers close to RSV vaccine

In addition to seniors, infants are at a higher risk of getting very sick with RSV.

The latest health and medical news emailed to you every Sunday.

There is no RSV vaccine for children, but there are two kinds of antibody injections that can be given to high-risk babies to help prevent serious illness.

One of them, palivizumab, has often been given to babies who were born prematurely _ but it needs to be injected about once a month during RSV season to stay effective.

A new antibody drug — nirsevimab, also known by the brand name Beyfortus — was approved by Health Canada in April. Nirsevimab only requires one injection to protect babies during the RSV season. It’s not yet known how widely it will be recommended for babies in Canada this fall.

Story continues below advertisement

On Thursday, the Centers for Disease Control and Prevention (CDC) in the U.S. recommended that babies born just before or during the RSV season, as well as babies who are less than eight months old before the season starts, should get the nirsevimab shot.

The CDC also recommended that the shot should be given to some eight to 19-month-old babies who are at higher risk of getting seriously ill from the virus.

— With files from Global News’ Naomi Barghiel and The Associated Press.

Sponsored content